Something's been nagging me about sentiment, so I went to Twitter to get to the bottom of it. Plus, what to expect from the Russell this week and a look at the S&P's head-and-shoulders top.
There's a long list of negatives that have created uncertainties the market will need time to fully discount.
I'm the most bullish I have been on risk and rates since earlier this year when we were looking for a short squeeze.
We remain constructive through year-end as inflation remains key and, we believe, on a glidepath lower.
With travelers and investors steering clear of China, look to Japan, and its leading airline in the months ahead.
Here's how I'd play the SPDR S&P Biotech exchange-traded fund.
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login